FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Robert Getzenberg

Research Profile

Disorders

Chemicals & Drugs

Anatomy

Living Beings

Co-author Network

Publications

TOP 3
John J Kim; Danielle Y Lee; Steven S An; Christhunesa S Christudass; Ben Fabry; Robert H Getzenberg; Krithika Rajagopalan; Takumi Shiraishi; Naoki Terada; Robert W Veltri; Bo Yin; Steven M Mooney
Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer.
Martin Aryee; G Steven Bova; Julia C Engelmann; David Esopi; Robert H Getzenberg; Meltem Gurel; Michael C Haffner; Rafael A Irizarry; William B Isaacs; Wennuan Liu; Jun Luo; William G Nelson; Philipp Nuhn; Jianfeng Xu; Srinivasan Yegnasubramanian
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.
Robert E Schoen; Lori J Sokoll; Daniel W Chan; Ahmed Magheli; Robert H Getzenberg
Retraction: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Robert Getzenberg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: John J Kim; Danielle Y Lee; Steven S An; Christhunesa S Christudass; Ben Fabry; Robert H Getzenberg; Krithika Rajagopalan; Takumi Shiraishi; Naoki Terada; Robert W Veltri; Bo Yin; Steven M Mooney
Acquisition of paclitaxel resistance is associated with a more aggressive and invasive phenotype in prostate cancer.
Journal of cellular biochemistry 2013;114(6):1286-93.
2013: Martin Aryee; G Steven Bova; Julia C Engelmann; David Esopi; Robert H Getzenberg; Meltem Gurel; Michael C Haffner; Rafael A Irizarry; William B Isaacs; Wennuan Liu; Jun Luo; William G Nelson; Philipp Nuhn; Jianfeng Xu; Srinivasan Yegnasubramanian
DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases.
Science translational medicine 2013;5(169):169ra10.
2013: Robert E Schoen; Lori J Sokoll; Daniel W Chan; Ahmed Magheli; Robert H Getzenberg
Retraction: Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(2):508.
2013: Robert E Schoen; Lori J Sokoll; Joel L Weissfeld; Grant W Cannon; Daniel W Chan; Robert H Getzenberg
Retraction. Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.
Cancer research 2013;73(2):1034.
2013: Gita Mahmoudabadi; Krithika Rajagopalan; Govindan Rangarajan; Robert H Getzenberg; Sridhar Hannenhalli; PRAKASH KULKARNI
Intrinsically disordered proteins and conformational noise: implications in cancer.
Cell cycle (Georgetown, Tex.) 2013;12(1):26-31.
2013: Michelle L Jones; Kenneth Pienta; Javed Siddiqui; Robert H Getzenberg
Circulating fibroblast-like cells in men with metastatic prostate cancer.
The Prostate 2013;73(2):176-81.
2012: Jie Li; Jun Luo; Christian P Pavlovich; Chang-Jun Yin; Robert H Getzenberg; Zhi-Hong Zhang; Wei Zhang
Effect of surgical procedures on prostate tumor gene expression profiles.
Asian journal of andrology 2012;14(5):708-14.
2012: PRAKASH KULKARNI; Steven M Mooney; Krithika Rajagopalan; Takumi Shiraishi; Robert Kim; Robert H Getzenberg
Cancer/testis antigens and urological malignancies.
Nature reviews. Urology 2012;9(7):386-96.
2012: Naoki Terada; David B Yeater; Yu Zeng; PRAKASH KULKARNI; Leslie A Mangold; Steven M Mooney; Alan W Partin; Takumi Shiraishi; Robert H Getzenberg
Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness.
The Prostate 2012;72(9):966-76.
2012: Robert H Getzenberg; H Ballentine Carter
Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer.
Asian journal of andrology 2012;14(3):347-8.
2012: Takumi Shiraishi; Robert H Getzenberg; PRAKASH KULKARNI
Cancer/testis antigens: novel tools for discerning aggressive and non-aggressive prostate cancer.
Asian journal of andrology 2012;14(3):400-4.
2012: Naoki Terada; PRAKASH KULKARNI; Robert H Getzenberg
Cyr61 is a potential prognostic marker for prostate cancer.
Asian journal of andrology 2012;14(3):405-8.
2012: Edward Messing; Howard Parnes; Daniel R Saltzstein; Joseph Tangrea; Marcia A Wheeler; Jay M Young; J Erik Busby; Anthony diSant'Agnese; Mitchell Efros; Adrienne Faerber; Jason R Gee; Robert H Getzenberg; Linda Harris; Thomas C Havighurst; Raymond Hohl; Margaret House; KyungMann Kim; Jill M Kolesar; Howard Bailey
A phase 2 cancer chemoprevention biomarker trial of isoflavone G-2535 (genistein) in presurgical bladder cancer patients.
Cancer prevention research (Philadelphia, Pa.) 2012;5(4):621-30.
2012: Michelle L Jones; William B Isaacsa; Charles M Ewing; Robert H Getzenberg
Prostate cancer-derived angiogenin stimulates the invasion of prostate fibroblasts.
Journal of cellular and molecular medicine 2012;16(1):193-201.
2011: Robert H Getzenberg; Donald S Coffey
Changing the energy habitat of the cancer cell in order to impact therapeutic resistance.
Molecular pharmaceutics 2011;8(6):2089-93.
2011: Krithika Rajagopalan; Robert H Getzenberg; Steven M Mooney; Nehal Parekh; PRAKASH KULKARNI
A majority of the cancer/testis antigens are intrinsically disordered proteins.
Journal of cellular biochemistry 2011;112(11):3256-67.
2011: Youqiang Li; Atsushi Mizokami; Steven M Mooney; Mikio Namiki; Bo Yin; Yu Zeng; Robert H Getzenberg
Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells.
Journal of cellular biochemistry 2011;112(8):2125-37.
2011: PRAKASH KULKARNI; Krithika Rajagopalan; David Yeater; Robert H Getzenberg
Protein folding and the order/disorder paradox.
Journal of cellular biochemistry 2011;112(7):1949-52.
2011: Liyu Liu; Bo Sun; Jonas N Pedersen; Koh-Meng Aw Yong; Robert H Getzenberg; Howard A Stone; Robert H Austin
Probing the invasiveness of prostate cancer cells in a 3D microfabricated landscape.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(17):6853-6.
2011: Yu Zeng; Yanan He; Fan Yang; Steven M Mooney; Robert H Getzenberg; John Orban; PRAKASH KULKARNI
The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein.
The Journal of biological chemistry 2011;286(16):13985-94.
2011: Steven Mooney; Krithika Rajagopalan; Brenten H Williams; Yu Zeng; Christhunesa S Christudass; Youqiang Li; Bo Yin; PRAKASH KULKARNI; Robert H Getzenberg
Creatine kinase brain overexpression protects colorectal cells from various metabolic and non-metabolic stresses.
Journal of cellular biochemistry 2011;112(4):1066-75.
2011: Takumi Shiraishi; Takahito Suyama; Naoki Terada; Bruce J Trock; Yu Zeng; PRAKASH KULKARNI; Jun Luo; Robert H Getzenberg
Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy.
Journal of translational medicine 2011;9():153.
2010: Katherine B D'Antonio; Lucianna Schultz; Roula Albadine; Alison M Mondul; Elizabeth A Platz; GEORGES NETTO; Robert H Getzenberg
Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(23):5908-13.
2010: Takahito Suyama; Takumi Shiraishi; Yu Zeng; Wayne Yu; Nehal Parekh; Robert L Vessella; Jun Luo; Robert H Getzenberg; PRAKASH KULKARNI
Expression of cancer/testis antigens in prostate cancer is associated with disease progression.
The Prostate 2010;70(16):1778-87.
2010: Robert H Getzenberg
Novel approaches for the molecular classification of prostate cancer.
Asian journal of andrology 2010;12(5):620-2.
2010: Robert H Getzenberg
Statins and the risk of prostate cancer or benign prostatic hyperplasia: biological plausibility.
The Journal of urology 2010;184(2):415-6.
2010: Liyu Liu; Kevin Loutherback; David Liao; David Yeater; Guillaume Lambert; André Estévez-Torres; James C Sturm; Robert H Getzenberg; Robert H Austin
A microfluidic device for continuous cancer cell culture and passage with hydrodynamic forces.
Lab on a chip 2010;10(14):1807-13.
2010: Katherine B D'Antonio; Antoun Toubaji; Roula Albadine; Alison M Mondul; Elizabeth A Platz; GEORGES NETTO; Robert H Getzenberg
Extracellular matrix associated protein CYR61 is linked to prostate cancer development.
The Journal of urology 2010;183(4):1604-10.
2010: Kazutoshi Fujita; Charles M Ewing; Robert H Getzenberg; J Kellogg Parsons; William B Isaacs; Christian P Pavlovich
Monocyte chemotactic protein-1 (MCP-1/CCL2) is associated with prostatic growth dysregulation and benign prostatic hyperplasia.
The Prostate 2010;70(5):473-81.
2009: Eddy S Leman; Ahmed Magheli; Koh Meng Aw Yong; George Netto; Stefan Hinz; Robert H Getzenberg
Identification of nuclear structural protein alterations associated with seminomas.
Journal of cellular biochemistry 2009;108(6):1274-9.
2009: Eddy S Leman; Robert H Getzenberg
Biomarkers for prostate cancer.
Journal of cellular biochemistry 2009;108(1):3-9.
2009: Eddy S Leman; Ahmed Magheli; Grant W Cannon; Leslie A Mangold; Alan W Partin; Robert H Getzenberg
Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2.
The Prostate 2009;69(11):1188-94.
2009: Takahiro Inoue; Atsushi Maeno; C Conover Talbot; Yu Zeng; David B Yeater; Eddy S Leman; PRAKASH KULKARNI; Osamu Ogawa; Robert H Getzenberg
Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells.
The Prostate 2009;69(8):861-73.
2009: Brian Keith McNeil; Robert H Getzenberg
Urinary protein biomarkers of cancer.
Expert opinion on medical diagnostics 2009;3(3):263-73.
2009: Yu Zeng; PRAKASH KULKARNI; Takahiro Inoue; Robert H Getzenberg
Down-regulating cold shock protein genes impairs cancer cell survival and enhances chemosensitivity.
Journal of cellular biochemistry 2009;107(1):179-88.
2009: PRAKASH KULKARNI; Robert H Getzenberg
High-fat diet, obesity and prostate disease: the ATX-LPA axis?
Nature clinical practice. Urology 2009;6(3):128-31.
2009: Robert H Getzenberg
Comment on "Treatment of chronic prostatitis in Chinese men" by Liang CZ et al. in Asian Journal of Andrology.
Asian journal of andrology 2009;11(2):149.
2009: Danil V Makarov; Stacy Loeb; Robert H Getzenberg; Alan W Partin
Biomarkers for prostate cancer.
Annual review of medicine 2009;60():139-51.
2008: Eddy S Leman; Robert H Getzenberg
Nuclear structure as a source of cancer specific biomarkers.
Journal of cellular biochemistry 2008;104(6):1988-93.
2008: Grant W Cannon; Robert H Getzenberg
Biomarkers for benign prostatic hyperplasia progression.
Current urology reports 2008;9(4):279-83.
2008: Robert H Getzenberg
What is the future of prostate-specific antigen for the early detection of prostate cancer?
BJU international 2008;102(2):157-8.
2008: Takahiro Inoue; Eddy S Leman; David B Yeater; Robert H Getzenberg
The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer.
The Prostate 2008;68(10):1048-56.
2008: Catherine A Thomas; Stephen G Grant; Beth R Pflug; Robert H Getzenberg; Billy W Day
(Z)-1,1-Dichloro-2-(4-methoxyphenyl)-3-phenylcyclopropane induces concentration-dependent growth inhibition, apoptosis, and coordinates regulation of apoptotic genes in TRAMP cells.
Urologic oncology 2008;26(4):378-85.
2008: Gisela Walgenbach-Brunagel; Bettina Burger; Eddy S Leman; Klaus-J Walgenbach; René H Tolba; Lukas Heukamp; Andreas Hirner; Robert H Getzenberg
The use of a colon cancer associated nuclear antigen CCSA-2 for the blood based detection of colon cancer.
Journal of cellular biochemistry 2008;104(1):286-94.
2008: Marko Babjuk; Viktor Soukup; Michael Pesl; M Kostírová; E Drncová; H Smolová; M Szakacsová; Robert H Getzenberg; Ivan Pavlík; J Dvorácek
Urinary cytology and quantitative BTA and UBC tests in surveillance of patients with pTapT1 bladder urothelial carcinoma.
Urology 2008;71(4):718-22.
2008: Chris Mullins; M Scott Lucia; Simon W Hayward; Jeannette Y Lee; Jonathan M Levitt; Victor K Lin; Brian C-S Liu; Arul M Chinnaiyan; Mark A Rubin; Kevin Slawin; robert star; Robert H Getzenberg
A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.
The Journal of urology 2008;179(4):1243-56.
2008: Eddy S Leman; Robert E Schoen; Ahmed Magheli; Lori J Sokoll; Daniel W Chan; Robert H Getzenberg
Evaluation of colon cancer-specific antigen 2 as a potential serum marker for colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(5):1349-54.
2008: Brian K McNeil; Robert H Getzenberg
Urine-based markers in bladder cancer: future prospects.
BJU international 2008;101(6):668-9.
2007: Evan T Keller; David R Rowley; Scott A Tomlins; Charles G Drake; Philip W Kantoff; Kenneth Pienta; James E Montie; H Ballentine Carter; Andrew M Hruszkewicz; Jorge Gomez; Suresh Mohla; Robert H Getzenberg
Eleventh Prouts Neck Meeting on Prostate Cancer: emerging strategies in prostate cancer therapy.
Cancer research 2007;67(20):9613-5.
2007: Eddy S Leman; Robert E Schoen; Joel L Weissfeld; Grant W Cannon; Lori J Sokoll; Daniel W Chan; Robert H Getzenberg
Initial analyses of colon cancer-specific antigen (CCSA)-3 and CCSA-4 as colorectal cancer-associated serum markers.
Cancer research 2007;67(12):5600-5.
2007: Glenn M Cannon; Manimaalha Balasudramani; Robert H Getzenberg
Characterization of nuclear matrix protein alterations associated with renal cell carcinoma.
Urology 2007;69(6):1227-30.
2007: Eddy S Leman; Grant W Cannon; Bruce J Trock; Lori J Sokoll; Daniel W Chan; Leslie A Mangold; Alan W Partin; Robert H Getzenberg
EPCA-2: a highly specific serum marker for prostate cancer.
Urology 2007;69(4):714-20.
2007: Grant W Cannon; Chris Mullins; M Scott Lucia; Simon W Hayward; Victor Lin; Brian C-S Liu; Kevin Slawin; Mark A Rubin; Robert H Getzenberg
A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia.
The Journal of urology 2007;177(2):610-4; discussion 614.
2006: Matthew Nielsen; Mark L Gonzalgo; Mark P Schoenberg; Robert H Getzenberg
Toward critical evaluation of the role(s) of molecular biomarkers in the management of bladder cancer.
World journal of urology 2006;24(5):499-508.
2006: Matthew Nielsen; Edward M Schaeffer; Robert W Veltri; Mark P Schoenberg; Robert H Getzenberg
Urinary markers in the detection of bladder cancer: what's new?
Current opinion in urology 2006;16(5):350-5.
2006: Donald S Coffey; Robert H Getzenberg; Theodore L DeWeese
Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect".
JAMA : the journal of the American Medical Association 2006;296(4):445-8.
2006: Glenn M Cannon; Robert H Getzenberg
Urinary matrix metalloproteinase activity is not significantly altered in patients with renal cell carcinoma.
Urology 2006;67(4):848-50.
2006: Manimalha Balasubramani; Billy W Day; Robert E Schoen; Robert H Getzenberg
Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer.
Cancer research 2006;66(2):763-9.
2005: Tomonori Habuchi; Michael Marberger; Michael J Droller; George P Hemstreet; H Barton Grossman; Jack A Schalken; Bernd J Schmitz-Dräger; William M Murphy; Aldo V Bono; Peter Goebell; Robert H Getzenberg; Stefan H Hautmann; Edward Messing; Yves Fradet; Vinata B Lokeshwar
Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers.
Urology 2005;66(6 Suppl 1):64-74.
2005: Vinata B Lokeshwar; Tomonori Habuchi; H Barton Grossman; William M Murphy; Stefan H Hautmann; George P Hemstreet; Aldo V Bono; Robert H Getzenberg; Peter Goebell; Bernd J Schmitz-Dräger; Jack A Schalken; Yves Fradet; Michael Marberger; Edward Messing; Michael J Droller
Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers.
Urology 2005;66(6 Suppl 1):35-63.
2005: Thu-Suong Van Le; Raymond Miller; Timothy Barder; Marko Babjuk; Douglas M Potter; Robert H Getzenberg
Highly specific urine-based marker of bladder cancer.
Urology 2005;66(6):1256-60.
2005: Benjamin Davies; Joseph Chen; Francesmary Modugno; Joel L Weissfeld; Douglas Landsittel; Rajiv Dhir; Joel Nelson; Robert H Getzenberg
Contribution of the prostate limits the usefulness of survivin for the detection of bladder cancer.
The Journal of urology 2005;174(5):1767-70.
2005: Benjamin Davies; Joseph J Chen; Timothy McMurry; Douglas Landsittel; Nancy Lewis; Gilbert Brenes; Robert H Getzenberg
Efficacy of BTA stat, cytology, and survivin in bladder cancer surveillance over 5 years in patients with spinal cord injury.
Urology 2005;66(4):908-11.
2005: Jiro Nagatomi; Fernando DeMiguel; Kazumasa Torimoto; Michael B Chancellor; Robert H Getzenberg; Michael S Sacks
Early molecular-level changes in rat bladder wall tissue following spinal cord injury.
Biochemical and biophysical research communications 2005;334(4):1159-64.
2005: Julie M Myers-Irvin; Thu-Suong Van Le; Robert H Getzenberg
Mechanistic analysis of the role of BLCA-4 in bladder cancer pathobiology.
Cancer research 2005;65(16):7145-50.
2005: Cynthia H Minnery; Robert H Getzenberg
Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen.
The Journal of urology 2005;174(1):375-9.
2005: Julie M Myers-Irvin; Douglas Landsittel; Robert H Getzenberg
Use of the novel marker BLCA-1 for the detection of bladder cancer.
The Journal of urology 2005;174(1):64-8.
2005: Daniel L Ouyang; Joseph J Chen; Robert H Getzenberg; Robert E Schoen
Noninvasive testing for colorectal cancer: a review.
The American journal of gastroenterology 2005;100(6):1393-403.
2005: Barbara Paul; Rajiv Dhir; Douglas Landsittel; Moira R Hitchens; Robert H Getzenberg
Detection of prostate cancer with a blood-based assay for early prostate cancer antigen.
Cancer research 2005;65(10):4097-100.
2005: Pradip Roy-Burman; Donald J Tindall; Diane M Robins; Norman M Greenberg; Mary J C Hendrix; Suresh Mohla; Robert H Getzenberg; John T Isaacs; Kenneth Pienta
Androgens and prostate cancer: are the descriptors valid?
Cancer biology & therapy 2005;4(1):4-5.
2004: Robert H Getzenberg
Commentary on: Mobley AJ, Lam YW, Lau KM, Pais VM, Lesperance JO, Steadman B, et al. Monitoring the serological Proteome Colon, the latest modality in prostate cancer detection. J Urol 2004; 172: 331-7.
Asian journal of andrology 2004;6(4):283.
2004: Meral Guzey; Jianhua Luo; Robert H Getzenberg
Vitamin D3 modulated gene expression patterns in human primary normal and cancer prostate cells.
Journal of cellular biochemistry 2004;93(2):271-85.
2004: Meral Guzey; Drazen M Jukic; Julie Arlotti; Marie Acquafondata; Rajiv Dhir; Robert H Getzenberg
Increased apoptosis of periprostatic adipose tissue in VDR null mice.
Journal of cellular biochemistry 2004;93(1):133-41.
2004: Uzma S Shah; Julie Arlotti; Rajiv Dhir; Sun Lu; Gregorio Pirozzi; Kulkarni Prakash; Robert H Getzenberg
Androgen regulation of JM-27 is associated with the diseased prostate.
Journal of andrology 2004;25(4):618-24.
2004: Yoshiyuki Kakehi; Takehiko Segawa; Xiu-Xian Wu; PRAKASH KULKARNI; Rajiv Dhir; Robert H Getzenberg
Down-regulation of macrophage inhibitory cytokine-1/prostate derived factor in benign prostatic hyperplasia.
The Prostate 2004;59(4):351-6.
2004: Shinji Sakamoto; Masahiro Yokoyama; Xianghua Zhang; Kulkarni Prakash; Kaori Nagao; Takashi Hatanaka; Robert H Getzenberg; Yoshiyuki Kakehi
Increased expression of CYR61, an extracellular matrix signaling protein, in human benign prostatic hyperplasia and its regulation by lysophosphatidic acid.
Endocrinology 2004;145(6):2929-40.
2004: Rajiv Dhir; Barbara N Vietmeier; Julie Arlotti; Marie Acquafondata; Douglas Landsittel; Robert Masterson; Robert H Getzenberg
Early identification of individuals with prostate cancer in negative biopsies.
The Journal of urology 2004;171(4):1419-23.
2004: Thu-Suong Van Le; Julie Myers; Badrinath R Konety; Timothy Barder; Robert H Getzenberg
Functional characterization of the bladder cancer marker, BLCA-4.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(4):1384-91.
2004: Gisela Brünagel; Robert E Schoen; Robert H Getzenberg
Colon cancer specific nuclear matrix protein alterations in human colonic adenomatous polyps.
Journal of cellular biochemistry 2004;91(2):365-74.
2004: Uzma S Shah; Robert H Getzenberg
Fingerprinting the diseased prostate: associations between BPH and prostate cancer.
Journal of cellular biochemistry 2004;91(1):161-9.
2003: Shinji Sakamoto; Masahiro Yokoyama; Kulkarni Prakash; Jun-Ichiro Tsuruha; Satoshi Masamoto; Robert H Getzenberg; Yoshiyuki Kakehi
Development of quantitative detection assays for CYR61 as a new marker for benign prostatic hyperplasia.
Journal of biomolecular screening 2003;8(6):701-11.
2003: Eddy S Leman; Julie Arlotti; Rajiv Dhir; Robert H Getzenberg
Vitamin D and androgen regulation of prostatic growth.
Journal of cellular biochemistry 2003;90(1):138-47.
2003: Masaaki Kasai; Jennifer Guerrero-Santoro; Robert Friedman; Eddy S Leman; Robert H Getzenberg; Donald B DeFranco
The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines.
Cancer research 2003;63(16):4927-35.
2003: Eddy S Leman; Fernando DeMiguel; Allen C Gao; Robert H Getzenberg
Regulation of androgen and vitamin d receptors by 1,25-dihydroxyvitamin D3 in human prostate epithelial and stromal cells.
The Journal of urology 2003;170(1):235-40.
2003: Gisela Brünagel; Uzma S Shah; Robert E Schoen; Robert H Getzenberg
Identification of calreticulin as a nuclear matrix protein associated with human colon cancer.
Journal of cellular biochemistry 2003;89(2):238-43.
2003: Eddy S Leman; Robert H Getzenberg
Effects of 1,25-dihydroxyvitamin D3 on the distribution of androgen and vitamin D receptors in human prostate neonatal epithelial cells.
Journal of cellular biochemistry 2003;88(3):609-22.
2003: Eddy S Leman; Michael C Madigan; Gisela Brünagel; Natsuki Takaha; Donald S Coffey; Robert H Getzenberg
Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer.
Journal of cellular biochemistry 2003;88(3):599-608.
2002: Gisela Brünagel; Robert E Schoen; Anthony Bauer; Barbara N Vietmeier; Robert H Getzenberg
Nuclear matrix protein alterations associated with colon cancer metastasis to the liver.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(10):3039-45.
2002: Badrinath R Konety; George Somogyi; Ali Atan; Josephia R Muindi; Michael B Chancellor; Robert H Getzenberg
Evaluation of intraprostatic metabolism of 1,25-dihydroxyvitamin D(3) (calcitriol) using a microdialysis technique.
Urology 2002;59(6):947-52.
2002: Kulkarni Prakash; Gregorio Pirozzi; Michael Elashoff; William E Munger; iwao waga; Rajiv Dhir; Yoshiyuki Kakehi; Robert H Getzenberg
Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(11):7598-603.
2002: Gisela Brünagel; Barbara N Vietmeier; Anthony Bauer; Robert E Schoen; Robert H Getzenberg
Identification of nuclear matrix protein alterations associated with human colon cancer.
Cancer research 2002;62(8):2437-42.
2002: Badrinath R Konety; Robert H Getzenberg
Vitamin D and prostate cancer.
The Urologic clinics of North America 2002;29(1):95-106, ix.
2002: Eddy S Leman; Robert H Getzenberg
Nuclear matrix proteins as biomarkers in prostate cancer.
Journal of cellular biochemistry 2002;86(2):213-23.
2002: Eddy S Leman; Julie Arlotti; Rajiv Dhir; Norman Greenberg; Robert H Getzenberg
Characterization of the nuclear matrix proteins in a transgenic mouse model for prostate cancer.
Journal of cellular biochemistry 2002;86(2):203-12.
2001: Badrinath R Konety; Robert H Getzenberg
Urine based markers of urological malignancy.
The Journal of urology 2001;165(2):600-11.
2001: D Krill; Petrina Deflavia; Rajiv Dhir; Jianhua Luo; Michael Becich; E Lehman; Robert H Getzenberg
Expression patterns of vitamin D receptor in human prostate.
Journal of cellular biochemistry 2001;82(4):566-72.
2001: Badrinath R Konety; John Lavelle; G Pirtskalaishvili; Rajiv Dhir; Susan A Meyers; TS Nguyen; Pamela A Hershberger; Michael R Shurin; Candace S Johnson; Donald L Trump; Mark L Zeidel; Robert H Getzenberg
Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo.
The Journal of urology 2001;165(1):253-8.
2000: Badrinath R Konety; Eddy S Leman; Barbara N Vietmeier; Julie Arlotti; Rajiv Dhir; Robert H Getzenberg
In vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate.
The Journal of urology 2000;164(5):1812-8.
2000: Badrinath R Konety; TS Nguyen; Gilbert Brenes; A Sholder; Nancy Lewis; Sheldon Bastacky; Douglas M Potter; Robert H Getzenberg
Clinical usefulness of the novel marker BLCA-4 for the detection of bladder cancer.
The Journal of urology 2000;164(3 Pt 1):634-9.
2000: Badrinath R Konety; TS Nguyen; Rajiv Dhir; Roger S Day; Michael Becich; W M Stadler; Robert H Getzenberg
Detection of bladder cancer using a novel nuclear matrix protein, BLCA-4.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2618-25.
2000: Badrinath R Konety; T T Nguyen; Gilbert Brenes; Nancy Lewis; Melissa I Saul; Joel B Nelson; Robert H Getzenberg
Evaluation of the effect of spinal cord injury on serum PSA levels.
Urology 2000;56(1):82-6.
2000: T Davido; Robert H Getzenberg
Nuclear matrix proteins as cancer markers.
Journal of cellular biochemistry. Supplement 2000;Suppl 35():136-41.
1999: G Pirtskalaishvili; Robert H Getzenberg; Badrinath R Konety
Use of urine-based markers for detection and monitoring of bladder cancer.
Techniques in urology 1999;5(4):179-84.
1999: G Pirtskalaishvili; Badrinath R Konety; Robert H Getzenberg
Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests?
Postgraduate medicine 1999;106(6):85-6, 91-4.
1999: Badrinath R Konety; AK Nangia; TS Nguyen; A Thomas; Robert H Getzenberg
Effect of prenatal vitamin D (calcitriol) exposure on the growth and development of the prostate.
The Prostate 1999;41(3):181-9.
1999: D Krill; J Stoner; Badrinath R Konety; Michael Becich; Robert H Getzenberg
Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture.
Urology 1999;54(1):171-7.
1999: Badrinath R Konety; C S Johnson; D L Trump; Robert H Getzenberg
Vitamin D in the prevention and treatment of prostate cancer.
Seminars in urologic oncology 1999;17(2):77-84.
1999: Michael J Horton; Robert H Getzenberg
Rat seminal-vesicle secretory protein SVS II binds DNA with a preference for the 5' regulatory region of secretory protein SVS IV gene: co-isolation with components of the nuclear matrix.
Journal of andrology 1999;20(2):267-79.
1999: Badrinath R Konety; Robert H Getzenberg
Nuclear structural proteins as biomarkers of cancer.
Journal of cellular biochemistry 1999;Suppl 32-33():183-91.
1998: Y Tang; Robert H Getzenberg; Barbara N Vietmeier; M R Stallcup; Martin Eggert; Rainer Renkawitz; Donald B DeFranco
The DNA-binding and tau2 transactivation domains of the rat glucocorticoid receptor constitute a nuclear matrix-targeting signal.
Molecular endocrinology (Baltimore, Md.) 1998;12(9):1420-31.
1998: AK Nangia; J L Butcher; Badrinath R Konety; Barbara N Vietmeier; Robert H Getzenberg
Association of vitamin D receptors with the nuclear matrix of human and rat genitourinary tissues.
The Journal of steroid biochemistry and molecular biology 1998;66(4):241-6.
1998: Jeffrey E Green; N M Greenberg; C L Ashendel; J C Barrett; C Boone; Robert H Getzenberg; J Henkin; R Matusik; T J Janus; Howard I Scher
Workgroup 3: transgenic and reconstitution models of prostate cancer.
The Prostate 1998;36(1):59-63.
1998: Badrinath R Konety; AK Nangia; TS Nguyen; B N Veitmeier; Rajiv Dhir; J S Acierno; Michael Becich; Ronald L Hrebinko; Robert H Getzenberg
Identification of nuclear matrix protein alterations associated with renal cell carcinoma.
The Journal of urology 1998;159(4):1359-63.
1997: Robert H Getzenberg; BW Light; P E Lapco; Badrinath R Konety; AK Nangia; J S Acierno; Rajiv Dhir; Z Shurin; Roger S Day; Donald L Trump; Candace S Johnson
Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system.
Urology 1997;50(6):999-1006.
1997: Badrinath R Konety; Robert H Getzenberg
Novel therapies for advanced prostate cancer.
Seminars in urologic oncology 1997;15(1):33-42.
1996: Badrinath R Konety; Gary G Schwartz; J S Acierno; Michael Becich; Robert H Getzenberg
The role of vitamin D in normal prostate growth and differentiation.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(11):1563-70.
1996: T S Replogle-Schwab; Robert H Getzenberg; T L Donat; Kenneth Pienta
Effect of organ site on nuclear matrix protein composition.
Journal of cellular biochemistry 1996;62(1):132-41.
1996: T A Nardozza; M M Quigley; Robert H Getzenberg
Association of transcription factors with the nuclear matrix.
Journal of cellular biochemistry 1996;61(3):467-77.
1996: Robert H Getzenberg; Badrinath R Konety; T A Oeler; M M Quigley; A Hakam; Michael Becich; R R Bahnson
Bladder cancer-associated nuclear matrix proteins.
Cancer research 1996;56(7):1690-4.
1996: R Replogle-Schwab; Kenneth Pienta; Robert H Getzenberg
The utilization of nuclear matrix proteins for cancer diagnosis.
Critical reviews in eukaryotic gene expression 1996;6(2-3):103-13.
1995: J L Osborn; Robert H Getzenberg; D L Trump
Spinal cord compression in prostate cancer.
Journal of neuro-oncology 1995;23(2):135-47.
1994: Michael A Reale; G Hu; A I Zafar; Robert H Getzenberg; S M Levine; Eric R Fearon
Expression and alternative splicing of the deleted in colorectal cancer (DCC) gene in normal and malignant tissues.
Cancer research 1994;54(16):4493-501.
1994: Robert H Getzenberg
Nuclear matrix and the regulation of gene expression: tissue specificity.
Journal of cellular biochemistry 1994;55(1):22-31.
1994: W E Pierceall; Kathleen R Cho; Robert H Getzenberg; Michael A Reale; L Hedrick; Bert Vogelstein; Eric R Fearon
NIH3T3 cells expressing the deleted in colorectal cancer tumor suppressor gene product stimulate neurite outgrowth in rat PC12 pheochromocytoma cells.
The Journal of cell biology 1994;124(6):1017-27.
1993: Alan W Partin; Robert H Getzenberg; M J CarMichael; D Vindivich; J Yoo; Jonathan I Epstein; Donald S Coffey
Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer.
Cancer research 1993;53(4):744-6.
1992: Kenneth Pienta; Robert H Getzenberg; Donald S Coffey
Characterization of nuclear morphology and nuclear matrices in ageing human fibroblasts.
Mechanisms of ageing and development 1992;62(1):13-24.
1991: Robert H Getzenberg; Kenneth Pienta; E Y Huang; Donald S Coffey
Identification of nuclear matrix proteins in the cancer and normal rat prostate.
Cancer research 1991;51(24):6514-20.
1991: Robert H Getzenberg; Kenneth Pienta; W S Ward; Donald S Coffey
Nuclear structure and the three-dimensional organization of DNA.
Journal of cellular biochemistry 1991;47(4):289-99.
1991: Robert H Getzenberg; Kenneth Pienta; E Y Huang; B C Murphy; Donald S Coffey
Modifications of the intermediate filament and nuclear matrix networks by the extracellular matrix.
Biochemical and biophysical research communications 1991;179(1):340-4.
1991: Kenneth Pienta; B C Murphy; Robert H Getzenberg; Donald S Coffey
The effect of extracellular matrix interactions on morphologic transformation in vitro.
Biochemical and biophysical research communications 1991;179(1):333-9.
1991: J Boyd; Kenneth Pienta; Robert H Getzenberg; Donald S Coffey; J Carl Barrett
Preneoplastic alterations in nuclear morphology that accompany loss of tumor suppressor phenotype.
Journal of the National Cancer Institute 1991;83(12):862-6.
1991: Kenneth Pienta; Robert H Getzenberg; Donald S Coffey
Cell structure and DNA organization.
Critical reviews in eukaryotic gene expression 1991;1(4):355-85.
1990: Robert H Getzenberg; Donald S Coffey
Tissue specificity of the hormonal response in sex accessory tissues is associated with nuclear matrix protein patterns.
Molecular endocrinology (Baltimore, Md.) 1990;4(9):1336-42.
1990: Robert H Getzenberg; Kenneth Pienta; Donald S Coffey
The tissue matrix: cell dynamics and hormone action.
Endocrine reviews 1990;11(3):399-417.
1987: P Nath; Robert H Getzenberg; D Beebe; L Pallansch; Peggy S Zelenka
c-myc mRNA is elevated as differentiating lens cells withdraw from the cell cycle.
Experimental cell research 1987;169(1):215-22.